科济全球首款实体瘤CAR-T获批之后 李宗海谈创新药可及性

中国经营网
Jul 25

99万定价,全球首款实体瘤CAR-T细胞疗法在中国获批。  一个月前,科济药业(2171.HK)自主研发的舒瑞基奥仑赛注射液获国家药监局批准上市,这是全球首款获批用于实体瘤治疗的CAR-T细胞治疗产品。  7月15日下午1点20分,科济药业位于上海徐汇区办公地址四楼的实验室大门被缓缓推开,公司创始人、董事长李宗海博士走了进来。他在百忙之中抽出时间接受了《中国经营报》记者的专访,聊起了中国实体瘤...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10